Main Street Research LLC Has $1.53 Million Stake in Eli Lilly and Company $LLY

Main Street Research LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 47.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,419 shares of the company’s stock after selling 1,262 shares during the quarter. Main Street Research LLC’s holdings in Eli Lilly and Company were worth $1,525,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of LLY. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its position in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Schnieders Capital Management LLC. grew its position in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares during the period. Flow Traders U.S. LLC acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $356,000. Finally, Nebula Research & Development LLC acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $749,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,066.59 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock’s fifty day simple moving average is $942.87 and its two-hundred day simple moving average is $1,004.53. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The stock has a market cap of $1.00 trillion, a PE ratio of 37.89, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period last year, the business earned $3.34 EPS. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Argus lifted their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research report on Monday, February 9th. CICC Research lifted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research report on Wednesday, February 11th. Guggenheim reissued a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday. Finally, Morgan Stanley reissued an “overweight” rating and issued a $1,344.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,220.37.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.